COMPARISON OF CYTOKERATIN FRAGMENT-19 (CYFRA-21-1), TISSUE POLYPEPTIDE ANTIGEN (TPA) AND CARCINOEMBRYONIC ANTIGEN (CEA) AS TUMOR-MARKERS INBRONCHOGENIC-CARCINOMA

Citation
Ms. Huang et al., COMPARISON OF CYTOKERATIN FRAGMENT-19 (CYFRA-21-1), TISSUE POLYPEPTIDE ANTIGEN (TPA) AND CARCINOEMBRYONIC ANTIGEN (CEA) AS TUMOR-MARKERS INBRONCHOGENIC-CARCINOMA, Respiratory medicine, 91(3), 1997, pp. 135-142
Citations number
32
Categorie Soggetti
Cardiac & Cardiovascular System","Respiratory System
Journal title
ISSN journal
09546111
Volume
91
Issue
3
Year of publication
1997
Pages
135 - 142
Database
ISI
SICI code
0954-6111(1997)91:3<135:COCF(T>2.0.ZU;2-0
Abstract
To elevate the diagnostic value of the serum cytokeratin 19 fragment ( CYFRA 21-1) and compare it with carcinoembryonic antigen (CEA) and tis sue polypeptide antigen (TPA) in bronchogenic carcinoma, the sera of 1 61 patients (58 with benign pulmonary disease and 103 with bronchogeni c carcinoma) was investigated using immunoradiometric assay. Sensitivi ties for CYFRA 21-1, CEA and TPA (using 3.5 ng ml(-1), 5.0 ng ml(-1), 110 Ul(-1), respectively, cut-off values corresponding to a 95% specif icity for benign pulmonary disease) in bronchogenic carcinoma were 64, 47 and 61%, respectively. Positive CYFRA 21-1 levels were identified in 75% of patients with squamous cell carcinoma (n=36), in 67% with ad enocarcinoma (n=45), iq 17% with large cell carcinoma (n=6), and in 50 % with small cell lung cancer (SCLC) (n=16). However, CYFRA 21-1 level s were not significantly different between squamous cell carcinoma and the other histological types. The sensitivity of the combined measure ment of CYFRA 21-1 with any other tumour marker was significantly high er than that of CYFRA 21-1 measurement alone. Elevated CYFRA 21-1 leve ls were observed in 44% of Stages I and II (n=18) and 72% of Stages II I and IV (n=69) patients with non-small cell lung cancer (P<0.05). A s ignificant inter-marker correlation was observed between CYFRA 21-1 an d TPA (n=103, r=0.448, P<0.0001). Twenty-one patients were monitored b y CYFRA 21-1, and significantly different changes in progressive patie nts (P=0.0058) and regressive patients (P=0.016) were obtained. These results indicate that CYFRA 21-1 may be not only a sensitive tumour ma rker in the diagnosis of bronchogenic carcinoma, but also a useful mar ker for the monitoring of bronchogenic carcinoma.